A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-20. Anything still debated is marked as such rather than presented as settled.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
There are several pressure-lowering medication groups that could be used in lowering the IOP, usually eyedrops. The choice of medication usually depends on the dose, duration, and side effects of each medication. However, in general, prostaglandin analogues are the first-line treatment for glaucoma. Prostaglandin analogues, such as latanoprost, bimatoprost, and travoprost, reduce the IOP by increasing the aqueous fluid outflow through the draining angle. It is usually prescribed once daily at night. The systemic side effects of this class are minimal. However, they can cause local side effects, including redness of the conjunctiva, a change in the iris color, and eyelash elongation. Several other classes of medications could be used as a second-line in case of treatment failure or presence of contraindications to prostaglandin analogues. These include:
2 BkO2 + H2 → Bk2O3 + H2O Upon heating to 1200 °C, the oxide Bk2O3 undergoes a phase change; it undergoes another phase change at 1750 °C. Such three-phase behavior is typical for the actinide sesquioxides. Berkelium(II) oxide, BkO, has been reported as a brittle gray solid but its exact chemical composition remains uncertain.
==== Dangers ==== If taken undiluted by mouth, GBL can cause esophageal and gastro-intestinal irritation. It is possible for oral ingestion of GBL to cause nausea and other similar problems, possibly more so than with GHB. GHB has biphasic effects, a euphoric effect at low doses (the reason for the term liquid ecstasy), and a sedative effect at higher doses. As a result of this sedation it can cause unconsciousness. When combined with alcohol the increased sedation and risk of vomiting results in a high risk of fatality. As a result, many harm reduction organizations suggest never mixing the two drugs. There have been several news reports of deaths associated with GBL, usually in combination with alcohol or other depressants.
Kort & Ricker (2026) compare pelvic morphology of Sinopa and Thinocyon with those of extant mammals, and argue that extant carnivorans might be imperfect analogs for reconstructions of configuration of musculature and locomotor modes of hyaenodonts. Fischer et al. (2026) study the body mass evolution in European mesonychians, hyaenodonts, oxyaenodonts and carnivoramorphs during the Paleogene, reporting evidence of increase of range of body mass of members of Carnivoramorpha after the Middle Eocene Climatic Optimum (and before the establishment of carnivoran-dominated faunas related to the Grande Coupure), and interpret the replacement of hyaenodont-dominated faunas in Europe by carnivoran-dominated ones as more likely related to climate changes than caused by competition between the different group of mammalian carnivores.
== Etymology == "Peritoneum" is derived from Greek: περιτόναιον, romanized: peritonaion, lit. 'peritoneum, abdominal membrane' via Latin. In Greek, περί, peri means "around", while τείνω, teino means "to stretch"; thus, "peritoneum" means "stretched over".
Sources: en.wikipedia.org
== Effects == The effects of strength training include greater muscular strength, improved muscle tone and appearance, increased endurance, cardiovascular health, and enhanced bone density. These benefits contribute not only to athletic performance but also to long-term health and independence, especially as individuals age. Regular resistance training supports metabolic function, helps regulate body weight, and can improve mental well-being through the release of endorphins.
The electoral process for the president was also changed, from being directly elected by the Togolese people to being indirectly elected by the Parliament. Opposition members criticised these changes due to the lack of term limits for Gnassingbé's new position. The changes came into effect in May 2025, when Gnassingbé was sworn in as president of the Council of Ministers, with former opposition leader Jean-Lucien Savi de Tové becoming president. Since June 2025, protests against Gnassingbé grew demanding his resignation. Gnassingbé has been widely criticized for contributing to democratic backsliding in Togo and critics have described him as a dictator.
=== Sulfonating agent === Sulfur trioxide is a potent sulfonating agent, i.e. it adds SO3 groups to substrates. Often the substrates are organic, as in aromatic sulfonation. For activated substrates, Lewis base adducts of sulfur trioxide are effective sulfonating agents.
A Ramachandran plot (also known as a Ramachandran diagram or a [φ,ψ] plot), originally developed in 1963 by G. N. Ramachandran, C. Ramakrishnan, and V. Sasisekharan, is a way to visualize energetically allowed regions for backbone dihedral angles ψ against φ of amino acid residues in protein structure. In a protein chain three dihedral angles are defined:
==== Slavery in the modern era ==== Brass, Tom; van der Linden, Marcel (1997). Free and unfree labour: the debate continues. Peter Lang. ISBN 978-3-906756-87-5. Brass, Tom (2015). Towards a Comparative Political Economy of Unfree Labour: Case Studies and Debates. Taylor & Francis. ISBN 978-1-317-82735-1. Bales, Kevin, ed. (2005). Understanding Global Slavery: A Reader. University of California Press. ISBN 978-0-520-93207-4. Bales, Kevin (2007). Ending Slavery: How We Free Today's Slaves. University of California Press. ISBN 978-0-520-25470-1. Craig, Gary (2007). Contemporary Slavery in the UK: Overview and Key Issues (PDF). York: Joseph Rowntree Foundation. ISBN 978-1-85935-573-2. Archived from the original (PDF) on June 14, 2007. Retrieved December 17, 2007. Hawk, David R. (2012). The Hidden Gulag: The Lives and Voices of "those Who Are Sent to the Mountains" (PDF). Washington, DC: U.S. Committee for Human Rights in North Korea. ISBN 978-0-615-62367-2. Archived from the original (PDF) on March 13, 2015. Retrieved September 21, 2012. Nazer, Mende; Lewis, Damien (2009). Slave: My True Story. PublicAffairs. ISBN 978-0-7867-3897-7. Sage, Jesse (2015). Enslaved: True Stories of Modern Day Slavery. St. Martin's Press. ISBN 978-1-250-08310-4. Sowell, Thomas (2010). "The Real History of Slavery". Black Rednecks and White Liberals. ReadHowYouWant.com. ISBN 978-1-4596-0221-2.
Sources: en.wikipedia.org
== Crime == Number of intentional homicides committed with a firearm that were recorded in criminal (police) statistics: Ranked 3rd for the year 2000 among the 92 countries that responded to the survey (behind #1 South Africa and #2 Colombia).
I. Partial-thickness defects A partial-thickness defect is a wound with adequate soft-tissue coverage of the underlying nasal skeleton, yet is too large for primary intention closure, with sutures. Based upon the locale of the wound, the surgeon has two options for correcting such a wound: (i) healing the wound by secondary intention (re-epithelialisation); and (ii) healing the wound with a full-thickness skin graft. Moreover, because it avoids the patched appearance of a skin-graft surgical correction, healing by secondary intention can successfully repair nasal wounds up to 10 mm in diameter; and, if the resultant scar proves aesthetically unacceptable, it can be revised later, after the wound has healed. In the event, larger nasal wounds (defects) do successfully heal by secondary intention, but do present two disadvantages. First, the resultant scar often is a wide patch of tissue that is aesthetically inferior to the scars produced with other nasal-defect correction techniques; however, the skin of the medial canthus is an exception to such scarring. The second disadvantage to healing by secondary intention is that the contracture of the wound might distort the normal nasal anatomy, which can lead to a pronounced deformity of the alar rim area. For this reason, healing by secondary intention generally is not recommended for defects of the distal third of the nose; nonetheless, the exception is a small wound directly upon the nasal tip.
== History == In the mid-twentieth century, mumps infections among children were not viewed as a serious public health issue, but adult men may develop debilitating testicular inflammation, which posed particular difficulty among close-quartered soldiers during wartime. As a result, during World War II (1939–1945), the United States government targeted mumps for scientific research. The first experimental mumps vaccine was licensed in 1948; developed from inactivated virus, it only had short-term effectiveness. Improved vaccines became commercially available in the 1960s. In 1963, Maurice Hilleman of Merck & Co. took samples of the mumps virus from his daughter, who had contracted the disease; she became the namesake for the resulting Jeryl Lynn strain. Building on then-recent advances that had led to vaccines for polio and measles, the mumps virus strains were developed in embryonic hens' eggs and chick embryo cell cultures. The resulting strains of virus were less well-suited for human cells, and are thus said to be attenuated. They are sometimes referred to as neuroattenuated in the sense that these strains are less virulent to human neurons than the wild strains. Hilleman's work led to the first effective mumps vaccine, called Mumpsvax. Licensed in 1967, its four-year development set a record for fastest development of a new vaccine, a record later surpassed by the COVID-19 vaccine, which was developed in less than a year.
Copyright infringement is the unauthorized or prohibited use of works under copyright, infringing the copyright holder's exclusive rights, such as the right to reproduce or perform the copyrighted work, or to make derivative works. Whilst almost universally considered under civil procedure, the impact and intent of organized criminal operations in this area of crime has been the subject of much debate. Article 61 of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) requires that signatory countries establish criminal procedures and penalties in cases of willful trademark counterfeiting or copyright piracy on a commercial scale. More recently copyright holders have demanded that states provide criminal sanctions for all types of copyright infringement. Organized criminal groups capitalize on consumer complicity, advancements in security and anonymity technology, emerging markets and new methods of product transmission, and the consistent nature of these provides a stable financial basis for other areas of organized crime.
== Education == Frank completed her M.D. and Ph.D. in biochemistry at the University of Pennsylvania. She completed a clinical pathology residency at the Brigham and Women's Hospital. During her postdoctoral research fellowship in immunology, she focused on V(D)J recombination in developing lymphocytes in the Howard Hughes Medical Institute laboratory of Frederick Alt at the Boston Children's Hospital. As a faculty member, her studies included DNA repair mechanisms relevant to both cancer and immunology, followed by microbiological investigations of Staphylococcus aureus and enterobacteriaceae.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.